| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Oncology | 21 | 2025 | 421 | 4.930 |
Why?
|
| Neoplasms | 36 | 2025 | 3334 | 4.800 |
Why?
|
| Colorectal Neoplasms | 33 | 2025 | 1103 | 3.980 |
Why?
|
| Healthcare Disparities | 11 | 2019 | 539 | 2.330 |
Why?
|
| Colonic Neoplasms | 15 | 2025 | 582 | 2.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2026 | 2658 | 2.010 |
Why?
|
| Drug Costs | 5 | 2020 | 66 | 1.810 |
Why?
|
| Adenocarcinoma | 17 | 2026 | 1211 | 1.600 |
Why?
|
| Patient Care Bundles | 3 | 2018 | 22 | 1.530 |
Why?
|
| Appendiceal Neoplasms | 8 | 2026 | 55 | 1.480 |
Why?
|
| Health Care Costs | 5 | 2019 | 256 | 1.420 |
Why?
|
| Rectal Neoplasms | 9 | 2024 | 138 | 1.370 |
Why?
|
| Health Care Reform | 5 | 2015 | 78 | 1.360 |
Why?
|
| Spiritual Therapies | 2 | 2021 | 8 | 1.320 |
Why?
|
| Antineoplastic Agents | 12 | 2021 | 2373 | 1.220 |
Why?
|
| Health Equity | 2 | 2023 | 116 | 1.220 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2017 | 75 | 1.150 |
Why?
|
| United States | 36 | 2025 | 8192 | 1.150 |
Why?
|
| Humans | 128 | 2026 | 98053 | 1.110 |
Why?
|
| Medicare | 9 | 2022 | 466 | 1.100 |
Why?
|
| Peritoneal Neoplasms | 7 | 2023 | 195 | 1.090 |
Why?
|
| Hyperthermia, Induced | 6 | 2023 | 77 | 1.060 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 480 | 1.040 |
Why?
|
| Advance Care Planning | 2 | 2018 | 45 | 1.020 |
Why?
|
| Clinical Trials as Topic | 7 | 2025 | 1129 | 1.000 |
Why?
|
| Stomach Neoplasms | 8 | 2025 | 319 | 0.990 |
Why?
|
| Minority Groups | 4 | 2017 | 156 | 0.980 |
Why?
|
| Religion | 2 | 2018 | 101 | 0.980 |
Why?
|
| Reimbursement Mechanisms | 6 | 2019 | 40 | 0.970 |
Why?
|
| Health Literacy | 2 | 2019 | 91 | 0.940 |
Why?
|
| Societies, Medical | 4 | 2018 | 682 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 601 | 0.870 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 417 | 0.830 |
Why?
|
| Patient Participation | 3 | 2022 | 246 | 0.750 |
Why?
|
| Survival Analysis | 5 | 2020 | 1527 | 0.740 |
Why?
|
| Middle Aged | 55 | 2026 | 29419 | 0.700 |
Why?
|
| Terminal Care | 2 | 2021 | 148 | 0.690 |
Why?
|
| Models, Economic | 3 | 2019 | 62 | 0.680 |
Why?
|
| Neuroendocrine Tumors | 4 | 2025 | 157 | 0.670 |
Why?
|
| Hockey | 1 | 2021 | 9 | 0.660 |
Why?
|
| American Cancer Society | 2 | 2017 | 15 | 0.650 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2016 | 57 | 0.640 |
Why?
|
| Aged | 52 | 2026 | 21750 | 0.640 |
Why?
|
| Male | 62 | 2026 | 47062 | 0.640 |
Why?
|
| Prognosis | 13 | 2026 | 4116 | 0.630 |
Why?
|
| Fluorouracil | 17 | 2026 | 541 | 0.630 |
Why?
|
| Female | 65 | 2026 | 51525 | 0.610 |
Why?
|
| Urban Population | 2 | 2018 | 246 | 0.600 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 175 | 0.590 |
Why?
|
| Health Expenditures | 2 | 2018 | 100 | 0.590 |
Why?
|
| Multimedia | 1 | 2019 | 9 | 0.590 |
Why?
|
| Racism | 1 | 2021 | 107 | 0.580 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 3272 | 0.570 |
Why?
|
| Insurance, Health | 2 | 2021 | 186 | 0.570 |
Why?
|
| Liver Neoplasms | 6 | 2025 | 831 | 0.570 |
Why?
|
| Cytoreduction Surgical Procedures | 9 | 2025 | 105 | 0.560 |
Why?
|
| Intestinal Neoplasms | 3 | 2025 | 77 | 0.560 |
Why?
|
| Social Justice | 1 | 2019 | 62 | 0.560 |
Why?
|
| Anus Neoplasms | 3 | 2026 | 41 | 0.530 |
Why?
|
| Organizational Objectives | 1 | 2017 | 23 | 0.530 |
Why?
|
| Glucuronosyltransferase | 4 | 2020 | 178 | 0.520 |
Why?
|
| Medicaid | 3 | 2017 | 276 | 0.520 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2017 | 280 | 0.510 |
Why?
|
| Health Personnel | 1 | 2020 | 257 | 0.510 |
Why?
|
| Metformin | 2 | 2018 | 132 | 0.510 |
Why?
|
| Social Class | 3 | 2021 | 156 | 0.510 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2017 | 66 | 0.510 |
Why?
|
| Survival Rate | 14 | 2026 | 2041 | 0.500 |
Why?
|
| Patient Care Team | 1 | 2020 | 320 | 0.500 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 169 | 0.500 |
Why?
|
| Health Services Accessibility | 6 | 2025 | 532 | 0.500 |
Why?
|
| Quality of Health Care | 3 | 2017 | 391 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2024 | 1099 | 0.490 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.490 |
Why?
|
| Health Status Disparities | 3 | 2020 | 234 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 769 | 0.490 |
Why?
|
| Health Services Research | 1 | 2017 | 145 | 0.490 |
Why?
|
| Internal-External Control | 1 | 2016 | 47 | 0.470 |
Why?
|
| Critical Pathways | 1 | 2016 | 36 | 0.470 |
Why?
|
| Health Policy | 2 | 2014 | 216 | 0.460 |
Why?
|
| Aged, 80 and over | 25 | 2026 | 7386 | 0.460 |
Why?
|
| Bevacizumab | 8 | 2022 | 255 | 0.460 |
Why?
|
| Neoplasm Staging | 15 | 2026 | 2080 | 0.460 |
Why?
|
| Biomedical Research | 2 | 2017 | 471 | 0.460 |
Why?
|
| Physicians | 2 | 2020 | 685 | 0.440 |
Why?
|
| Mortality, Premature | 1 | 2015 | 6 | 0.440 |
Why?
|
| Leucovorin | 12 | 2025 | 205 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2026 | 1535 | 0.430 |
Why?
|
| Precision Medicine | 3 | 2018 | 503 | 0.430 |
Why?
|
| Chemoprevention | 1 | 2014 | 93 | 0.410 |
Why?
|
| Heart Arrest | 1 | 2017 | 321 | 0.390 |
Why?
|
| Ambulatory Care | 1 | 2015 | 201 | 0.390 |
Why?
|
| Patient-Centered Care | 3 | 2025 | 233 | 0.380 |
Why?
|
| Intensive Care Units | 1 | 2016 | 520 | 0.360 |
Why?
|
| Hospitalization | 2 | 2016 | 991 | 0.360 |
Why?
|
| Adult | 34 | 2026 | 29529 | 0.350 |
Why?
|
| Treatment Outcome | 23 | 2024 | 9708 | 0.340 |
Why?
|
| Palliative Care | 3 | 2023 | 290 | 0.340 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 412 | 0.340 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 663 | 0.340 |
Why?
|
| Patient Care | 1 | 2012 | 99 | 0.340 |
Why?
|
| Mass Screening | 7 | 2021 | 745 | 0.340 |
Why?
|
| Retrospective Studies | 19 | 2026 | 10960 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2026 | 4025 | 0.320 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 403 | 0.320 |
Why?
|
| Spirituality | 2 | 2021 | 111 | 0.300 |
Why?
|
| Combined Modality Therapy | 9 | 2024 | 1751 | 0.300 |
Why?
|
| Early Detection of Cancer | 5 | 2021 | 550 | 0.300 |
Why?
|
| Algorithms | 1 | 2018 | 2002 | 0.300 |
Why?
|
| Camptothecin | 5 | 2022 | 198 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 682 | 0.290 |
Why?
|
| Costs and Cost Analysis | 3 | 2022 | 155 | 0.290 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 207 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 5 | 2021 | 1416 | 0.280 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 3021 | 0.280 |
Why?
|
| Mutation | 5 | 2026 | 4392 | 0.270 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 112 | 0.270 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 353 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2026 | 1764 | 0.270 |
Why?
|
| SEER Program | 2 | 2006 | 243 | 0.270 |
Why?
|
| Prospective Studies | 10 | 2022 | 4823 | 0.270 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 428 | 0.270 |
Why?
|
| Disease-Free Survival | 9 | 2022 | 1193 | 0.260 |
Why?
|
| Capecitabine | 4 | 2026 | 103 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 811 | 0.260 |
Why?
|
| Decision Making | 3 | 2018 | 686 | 0.260 |
Why?
|
| Income | 2 | 2019 | 101 | 0.250 |
Why?
|
| Government Regulation | 2 | 2019 | 49 | 0.250 |
Why?
|
| Forecasting | 2 | 2017 | 295 | 0.240 |
Why?
|
| Chromogranins | 1 | 2026 | 17 | 0.240 |
Why?
|
| Organoplatinum Compounds | 6 | 2018 | 95 | 0.240 |
Why?
|
| Incidence | 4 | 2017 | 1777 | 0.230 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2026 | 24 | 0.230 |
Why?
|
| Ipilimumab | 1 | 2026 | 68 | 0.230 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 305 | 0.230 |
Why?
|
| Somatostatin | 1 | 2025 | 61 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2006 | 124 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2026 | 1105 | 0.220 |
Why?
|
| Case-Control Studies | 4 | 2017 | 1995 | 0.220 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2025 | 42 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2025 | 53 | 0.220 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 11 | 0.220 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 26 | 0.210 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 32 | 0.210 |
Why?
|
| Hepatic Artery | 1 | 2025 | 84 | 0.210 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 194 | 0.210 |
Why?
|
| Octreotide | 2 | 2024 | 32 | 0.210 |
Why?
|
| Cholangiocarcinoma | 1 | 2025 | 83 | 0.210 |
Why?
|
| Cohort Studies | 9 | 2023 | 3212 | 0.210 |
Why?
|
| Bile Duct Neoplasms | 1 | 2025 | 96 | 0.200 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 125 | 0.200 |
Why?
|
| Risk Factors | 7 | 2017 | 6231 | 0.200 |
Why?
|
| Chicago | 5 | 2020 | 1513 | 0.200 |
Why?
|
| Pharmacogenetics | 2 | 2018 | 472 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 478 | 0.200 |
Why?
|
| Benzimidazoles | 1 | 2024 | 118 | 0.190 |
Why?
|
| Surgical Oncology | 1 | 2023 | 34 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 264 | 0.190 |
Why?
|
| Appendix | 1 | 2023 | 33 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 244 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 1090 | 0.180 |
Why?
|
| Neoplasm Metastasis | 5 | 2019 | 1089 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 903 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 82 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 384 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 523 | 0.170 |
Why?
|
| Cetuximab | 3 | 2017 | 119 | 0.170 |
Why?
|
| Food Quality | 1 | 2020 | 1 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 922 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 21 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 23 | 0.160 |
Why?
|
| Adiponectin | 1 | 2020 | 22 | 0.160 |
Why?
|
| ras Proteins | 2 | 2011 | 137 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 556 | 0.160 |
Why?
|
| Coordination Complexes | 1 | 2020 | 20 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2020 | 414 | 0.160 |
Why?
|
| Death | 1 | 2021 | 98 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 118 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 321 | 0.150 |
Why?
|
| Metastasectomy | 1 | 2019 | 10 | 0.150 |
Why?
|
| Pharmacists | 1 | 2020 | 42 | 0.150 |
Why?
|
| Nigeria | 1 | 2020 | 174 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 190 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2023 | 381 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 157 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 658 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 839 | 0.140 |
Why?
|
| Research Design | 2 | 2025 | 660 | 0.140 |
Why?
|
| Self Efficacy | 1 | 2019 | 65 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 37 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 308 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 314 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2015 | 41 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 369 | 0.130 |
Why?
|
| Hematology | 1 | 2018 | 37 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 237 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2018 | 97 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2017 | 239 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2457 | 0.130 |
Why?
|
| Organ Preservation | 3 | 2024 | 139 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 150 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2019 | 224 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 40 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2021 | 351 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 30 | 0.130 |
Why?
|
| Cost Savings | 2 | 2014 | 68 | 0.130 |
Why?
|
| Sirolimus | 1 | 2018 | 182 | 0.130 |
Why?
|
| Quality of Life | 3 | 2021 | 1895 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2018 | 217 | 0.120 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2016 | 28 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 155 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2011 | 413 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 132 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 831 | 0.120 |
Why?
|
| Age Factors | 3 | 2019 | 1962 | 0.120 |
Why?
|
| Exercise | 1 | 2019 | 380 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2016 | 67 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 156 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1012 | 0.110 |
Why?
|
| Physician's Role | 1 | 2017 | 181 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 802 | 0.110 |
Why?
|
| Educational Status | 1 | 2016 | 205 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 82 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2015 | 75 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 665 | 0.110 |
Why?
|
| Episode of Care | 1 | 2014 | 9 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2016 | 164 | 0.110 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 337 | 0.110 |
Why?
|
| Commerce | 1 | 2014 | 29 | 0.110 |
Why?
|
| Specialization | 1 | 2015 | 69 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 246 | 0.110 |
Why?
|
| Politics | 1 | 2015 | 54 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2018 | 594 | 0.100 |
Why?
|
| Colon | 1 | 2018 | 562 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 1275 | 0.100 |
Why?
|
| Health Insurance Exchanges | 1 | 2014 | 2 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2014 | 91 | 0.100 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 259 | 0.100 |
Why?
|
| Social Support | 1 | 2016 | 246 | 0.100 |
Why?
|
| Eligibility Determination | 1 | 2014 | 41 | 0.100 |
Why?
|
| Policy Making | 1 | 2014 | 64 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1109 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 5567 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 356 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 412 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.100 |
Why?
|
| Delaware | 1 | 2013 | 2 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 184 | 0.100 |
Why?
|
| Comorbidity | 2 | 2022 | 1031 | 0.090 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 90 | 0.090 |
Why?
|
| New York | 1 | 2013 | 79 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2012 | 20 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 265 | 0.090 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2019 | 483 | 0.090 |
Why?
|
| Patents as Topic | 1 | 2012 | 12 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2014 | 152 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 193 | 0.090 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 685 | 0.090 |
Why?
|
| Peptides | 1 | 2015 | 669 | 0.090 |
Why?
|
| Alanine | 1 | 2012 | 82 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 193 | 0.090 |
Why?
|
| Triazines | 1 | 2012 | 55 | 0.090 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 22 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 898 | 0.080 |
Why?
|
| Ploidies | 1 | 2011 | 39 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 84 | 0.080 |
Why?
|
| Cost Sharing | 1 | 2011 | 20 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2025 | 164 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 126 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 72 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1284 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 169 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 7504 | 0.080 |
Why?
|
| Vitamin D | 1 | 2013 | 285 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 1888 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2010 | 230 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1009 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 976 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 764 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 525 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 1610 | 0.070 |
Why?
|
| Microsatellite Instability | 2 | 2024 | 68 | 0.070 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 61 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2011 | 516 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 354 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1836 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 200 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2558 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 300 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 450 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1782 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2009 | 850 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 640 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 1138 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 272 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2006 | 65 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2022 | 674 | 0.060 |
Why?
|
| Canada | 2 | 2017 | 211 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 128 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2006 | 191 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2020 | 282 | 0.060 |
Why?
|
| Patient Safety | 2 | 2019 | 235 | 0.060 |
Why?
|
| Age of Onset | 1 | 2026 | 367 | 0.060 |
Why?
|
| Benzamides | 1 | 2006 | 260 | 0.050 |
Why?
|
| Culture | 1 | 2005 | 57 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2006 | 578 | 0.050 |
Why?
|
| Age Distribution | 1 | 2005 | 208 | 0.050 |
Why?
|
| Piperazines | 1 | 2006 | 306 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 59 | 0.050 |
Why?
|
| Patient Selection | 2 | 2018 | 725 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1950 | 0.050 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Microwaves | 1 | 2023 | 45 | 0.050 |
Why?
|
| Peritoneum | 1 | 2023 | 52 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2019 | 2585 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1088 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2023 | 203 | 0.040 |
Why?
|
| Monoterpenes | 1 | 2022 | 6 | 0.040 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 580 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 57 | 0.040 |
Why?
|
| Celecoxib | 1 | 2022 | 34 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 285 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 135 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 377 | 0.040 |
Why?
|
| Adolescent | 3 | 2025 | 10077 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 201 | 0.040 |
Why?
|
| Cause of Death | 1 | 2022 | 278 | 0.040 |
Why?
|
| Occult Blood | 1 | 2021 | 29 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2021 | 75 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2020 | 220 | 0.040 |
Why?
|
| C-Peptide | 1 | 2020 | 191 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 522 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 461 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 726 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 984 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 1061 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 469 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 127 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 142 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 306 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 169 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 38 | 0.040 |
Why?
|
| Markov Chains | 1 | 2019 | 146 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 96 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 46 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 166 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 250 | 0.030 |
Why?
|
| Filgrastim | 1 | 2017 | 56 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 72 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 317 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 213 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 44 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 97 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 551 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 336 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 220 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 236 | 0.030 |
Why?
|
| Stakeholder Participation | 1 | 2016 | 26 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 413 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 95 | 0.030 |
Why?
|
| Snake Venoms | 1 | 2015 | 10 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1145 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 81 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 382 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 520 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 418 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 402 | 0.030 |
Why?
|
| Pyrroles | 1 | 2015 | 165 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 310 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 102 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 656 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 442 | 0.020 |
Why?
|
| Indoles | 1 | 2015 | 334 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 754 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 50 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 32 | 0.020 |
Why?
|
| Appetite | 1 | 2012 | 21 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2012 | 28 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 48 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 217 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 94 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 355 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 38 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 70 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 187 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 548 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1254 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 601 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2036 | 0.010 |
Why?
|
| Hypertension | 1 | 2012 | 778 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 28893 | 0.010 |
Why?
|